Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 616

1.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
2.

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.

Can J Urol. 2007 Jun;14(3):3551-9.

PMID:
17594745
3.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

4.

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.

Cancer. 2004 Mar 1;100(5):892-9. Review.

5.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
6.
7.

Fracture risk in patients with prostate cancer on androgen deprivation therapy.

López AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA.

Osteoporos Int. 2005 Jun;16(6):707-11. Epub 2005 Feb 16.

PMID:
15714259
8.

Osteoporosis due to androgen deprivation therapy in men with prostate cancer.

Daniell HW.

Urology. 2001 Aug;58(2 Suppl 1):101-7. Review.

PMID:
11502461
9.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

PMID:
21807761
10.

Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.

Tanvetyanon T.

Cancer. 2005 Jan 15;103(2):237-41. Erratum in: Cancer. 2006 Jun 1;106(11):2530.

11.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
12.
13.

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.

Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P, Duff-Canning S, Krahn M, Naglie G, Tannock I, Tomlinson G, Alibhai SM.

BJU Int. 2009 Mar;103(6):753-7. doi: 10.1111/j.1464-410X.2008.08156.x. Epub 2008 Oct 24.

14.

Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy.

Ziaran S, Goncalves FM, Wendl J, Trebaticky B, Breza JS.

Bratisl Lek Listy. 2009;110(9):559-62.

PMID:
19827339
15.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.

PMID:
19758618
16.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

17.

Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.

Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.

Cancer. 2004 Aug 1;101(3):541-9. Erratum in: Cancer. 2004 Nov 15;101(10):2370.

18.

Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.

Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, Galì A, Frisina N, Melloni D.

Eur Urol. 2005 May;47(5):575-80; discussion 580-1.

PMID:
15826746
19.

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.

BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.

20.

Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA.

Urology. 1999 Oct;54(4):607-11.

PMID:
10510915
Items per page

Supplemental Content

Write to the Help Desk